About Cilia- and flagella-associated protein 54
Cilia- and flagella-associated protein 54 (CFAP54) is a protein
from Homo sapiens identified by UniProt accession
Q96N23, 3096 residues long.
MolForge cross-references it against 0 known binders and
112 disease associations.
Target properties
| Protein name | Cilia- and flagella-associated protein 54 |
|---|
| UniProt accession | Q96N23 |
|---|
| Gene | CFAP54 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 3096 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (112)
Diseases linked to this target (Open Targets).
- phospholipid measurement · score 0.30
- adolescent idiopathic scoliosis · score 0.18
- azoospermia · score 0.08
- gut microbiome measurement · score 0.07
- male infertility with teratozoospermia due to single gene mutation · score 0.06
- self reported educational attainment · score 0.05
- partial chromosome Y deletion · score 0.05
- mathematical ability · score 0.05
- body mass index · score 0.05
- body height · score 0.05
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
Amino-acid sequence (3096 residues)
MAAQGSPSSS PSDDSTTSGS LPELPPTSTA TSRSPPESKG SSRSSLLQWT CPEDSLPLAV FYGPLDAKNP LLASCEKEIQ ELLGFMRKKK ALATTEEEKH EFRRRCATSL FNIWTKYAPR LPADYYNEKL LKVGDSLCQM KEYKLALLQC YGRYLQQFNT NFDENKVDVT QFKATFFPKG FKDKTAGLTF HALSGKNMCN YQLVCDSDEN LKNKESVVQC LHILSSLRLI MQVALPQEHL CWIIFNGTIY IYTICRKLMV IGQSSKALEY LLWASMCMES LVPLLSLRYL TWRATLYTAV CQCCYDCHAG IHGEAFARRA LAKIDELRQL ELMSSSKSQE ESRRYFREAT MKMAVMIFKR GVFESRRKNK AVFRPKIRIN LREVQTLSWP RTVTERLLDE MFDSTASQFL AVLEALSDSN RRILQTGPIV TDEVEIHDVV SELFMAGKEL LIMSNIGADG MLDFPKTSLL ELMIGRKDVI SVDAAVKFIK LAFTYEEWSL FESSAVHLIY FLQRQDDPES KKAEKDLTLL IAMEPLINVK RNKGLIFPLE NYKEGQSTQI YLKKIAVHDT CLKTCGYSED IFHLAATLYV CVCTAPQDVQ PDKEIVVDTI MFLWQKCKLG IQRLNISRND YAKFTQKIST NKWIYLLWQI NEVIHCYKME DIDIVVVAEV TLRLSEILES LGSPGRKFKQ SLDVPLREGT NKFPGAPKGI TEILPILQKN PVEQLLFAYK LLDRAIGGIN LNCMLTSLPN GSSVIDHCYA KRTHHIDGDT YKPLASNSFM MDLHLELIQA QHRIAVVLLD KLQVLQTPTV SKDISTKGPE KLKQSGSTDC FTELNIMNKI KKNTLSKAIY LMQKALLIFE KDATSTSSWE LLMEAYSLIQ RIEAEQNALY SYQKYLESSK RKKSRVPPPP ILLSRTHCSV TLKPAPFTSE VKVSWYCILG CKAEGSYGKV RLNNNHLPNS GEAIPADGKS VFEVKGLETN EKYVFAVAAY SNNGKLVGGA IGETTKPILV YPPLSTITAR MFLTQVAYQV GNYELAKKVF SPVWDYFVAS PLQDEQSVIC LSNIITITQR RLHSDILAET SSILLYLFLR NIFVTSDIKI KEENLFCDNI KGNEIFPSQQ IARLIECERV LVALELSNFL NDSSYALQAV TQCYGLLAPI IYHNIVLVPV VQILIKCIVV LQGLPSIVCS KKHTASFESI QHMIACCIFY ITKILRSWRE YDLAVMIINY GKKMLDITPG CKSLFDGSNE QEEMPEEDSS KKSLKTKKPQ QILLPEKINE QLALLETHLL KLTKQYVTSE LSGGEDPIFL YPVVLNWSVK GAVKEVMKFK QKPRFLEFFT QVMLKCMNEE KFHLMVEVTT PVHDFLKRRN ESLLGLIKVK YKDSALNKKA NKSLKFKAAV MEIGRSAEMQ QRIRSKKKET LRDFIFKNPA ISEMVAHERN RRTSVRKAAQ RYLMDYLNPL ILSYVKRKRF HRLSLEEMPW RAQMNLYLAG AHFNLVLQKL WECTKMKFGT SHMMVSFRSC DPNMFSLYNS GTVLPTRKLT VENYKAMLDF LLTAKKRKAN LPSDAEEFST FINSIMSDEN MSKTQTVYDS DSQSGSSAKE KDRGANLCVM DHFMKIFLYC RRAMVLAHRG GYWTLLQNCC RALWNFTQEL QILLKQAVDL DKTFPISQDG FLCTSVLPFY LGAELLIDML IQLQNTSSIK PIEDKGEFSV PSCYGNIKND NGGSSLTFEH PLDDVNVVDL KWIHDFVLKS LEVLYQVEKW ETLVSLAIQF NTVSHERYTE QVTPLLVYAQ RQLLLRIQKF KGPDITQQPC ARYEAEYGEK ITCRNFIGKQ LKINSSTIEA TSNCTDLLKM LISSEYSRAK ALVCVPVDVT DTLRCFRETL EKSKYHNRSI RHSRKLLSLF LAQTQDVLQA SNQRSLKVQA LHSLGSLLIF AEKKRAAFKC WCQALDDIFR KPDVLHTWKE FGPSLTNVTN SHSPPGFKDY SEEFLSRVGI WGCLQGAVIS AKIAQFIKSL NVEKKTDCCI LSALLFQGLL RTTLPHPKAE RCYAQYEITQ LLPGIELFSD RYRADICSVI ASLYYIIREL HFVRQNLIVL PLLALYQYFV SGICQDITRN LEARILKIEV LIDLRFFSEA FYEISQIFYG KNMPCPIPAG YKATGKMKIF QSFDSGKLLT SKENIQAIDE LRNKGLPAVL VTIGQPHLLN KFNFVKAYFF LSVAATINCV PENKFKTVIT NKSKPNLPNL EEIYSKDDGS SFYNLTKLKD EITLSMLKSM LLMEAEDRLN FLLSEVEQKT LSQCSAGELE IVVEARLQLA AVALQRHRAA YSAAIVFSTL TLLQDSKLFE KKVVQDDTEN PVSPGTSVTE NKDDSEFLDP ISLNAREYFN IHLWLRCRLA LVTAFVAQIH GIGIVKEDDM TDCLSLINEV CMEAKSAGDT ELQAEFLTQA VILGLQEKHL KADIMTNLQD IIHLLEGNEF ISPQSRLTLA RSLVLLDDLT KAEKFKESPS SKTGKLNLLT RAHSILTEQM LAFGETIEFR SSNTKYANPL QPLKNIYLPH VMLLAKIKMR IGHTVAKQVY YKNKRKDPSK WLPALHLFDV ALKLCRTTAV EEHEVEAEIL FQKGKIERQI LMEEKSPSFQ LESLYEAIQL SLKNDQNSGL IRDSYLEMAL LYFHLKKPKI KISGSPLTLK PPLRRSSSVK ETSANKFEMY SSLAWIAIRA AAQVSEAVLA INLLIGKKNT RMHKVNQVAL PNIPEFAALD LLSSYTDYLL DNYQVLFQTS CTFLYQNDDV CDSADGRKKT QTKVDITWIL LLRYYIHLQR INNLSKLLAS ATPVSGISLP DDTLLTSLYN SELILRQKEV HFFLKKFLQL YSSSCIDEFP KELLCQLENP PLSEKDLRES SAKLYRDSSV QSILSFKPVS GSSCVDITPI EMVTQASNKE LCFQWYIPPL DRPPKETEPM VLLLYAYNLK PLKISDVRHS TYNSTCVGSL WIPLNRVIAI HEKLSNLAQI AELSLPAAPE ITSNENIYEV EVEEESVDNE MEDMIIQCCS EIASLFLNDK EPTPLSEVPF DISLPSIFNL ERLFDLANGC ILSGGSLFNW IVSIIP
Explore Cilia- and flagella-associated protein 54 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets